A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer

被引：0
|
作者：
Ai, X. [1 ]
Pan, Y. [2 ]
Shi, J. [3 ]
Yang, N. [4 ]
Liu, C. [5 ]
Zhou, J. [6 ]
Zhang, X. [7 ]
Dong, X. [8 ]
He, J. [9 ]
Li, X. [10 ,12 ]
Chen, G. [11 ]
Li, X. [10 ,12 ]
Zhang, H. [13 ]
Liao, W. [14 ]
Zhang, Y. [15 ]
Ma, Z. [16 ]
Zhang, B. [17 ]
Zhang, D. [17 ]
Lu, S. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[2] Anhui Prov Hosp, Dept Chemotherapy, Hefei, Anhui, Peoples R China
[3] Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China
[4] Hunan Canc Hosp, Lung & Gastrointestinal Oncol Dept, Changsha, Hunan, Peoples R China
[5] Xinjiang Med Univ, Canc Hosp, Dept Pulm Med, Urumqi, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Hangzhou, Zhejiang, Peoples R China
[7] Nantong Tumor Hosp, Dept Med Oncol, Nantong, Peoples R China
[8] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Hubei, Peoples R China
[9] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China
[10] Liaoning Canc Hosp & Inst, Dept Thorac Med, Shenyang, Peoples R China
[11] Harbin Med Univ Canc Hosp, Dept Resp Med, Harbin, Heilongjiang, Peoples R China
[12] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Henan, Peoples R China
[13] Tangdu Hosp, Dept Oncol, Xian, Shaanxi, Peoples R China
[14] Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[15] Zhejiang Canc Hosp, Dept Thorac Medial Oncol, Hangzhou, Zhejiang, Peoples R China
[16] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[17] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.371
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
377O
引用
收藏
页码：S1387 / S1387
页数：1
相关论文
共 50 条
  • [31] Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
    Langer, Corey J.
    Albert, Istvan
    Ross, Helen J.
    Kovacs, Peter
    Blakely, L. Johnetta
    Pajkos, Gabor
    Somfay, Attila
    Zatloukal, Petr
    Kazarnowicz, Andrzei
    Moezi, Mehdi M.
    Schreeder, Marshall T.
    Schnyder, Judy
    Ao-Baslock, Ada
    Pathak, Ashutosh K.
    Berger, Mark S.
    LUNG CANCER, 2014, 85 (03) : 420 - 428
  • [32] A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer
    Kalemkerian, GP
    Ali, MA
    Luthra, K
    Wozniak, AJ
    Valdivieso, M
    Kraut, MJ
    CANCER INVESTIGATION, 2001, 19 (03) : 234 - 238
  • [33] Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)
    Jalal, Shadia I.
    Lavin, Philip
    Lo, Gregory
    Lebel, Francois
    Einhorn, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2619 - +
  • [34] Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer
    Konala, Venu Madhav
    Madhira, Bhaskar Reddy
    Ashraf, Sara
    Graziano, Stephen
    ONCOLOGY, 2020, 98 (11) : 749 - 754
  • [35] A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer
    Chen, TT
    Chute, JP
    Feigal, E
    Johnson, BE
    Simon, R
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19): : 1601 - 1607
  • [36] Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Johnson, Elizabeth A.
    Marks, Randolph S.
    Mandrekar, Sumithra J.
    Hillman, Shauna L.
    Hauge, Mark D.
    Bauman, Mitchel D.
    Wos, Edward J.
    Moore, Dennis F.
    Kugler, John W.
    Windschitl, Harold E.
    Graham, David L.
    Bernath, Albert M., Jr.
    Fitch, Tom R.
    Soori, Gamini S.
    Jett, James R.
    Adjei, Alex A.
    Perez, Edith A.
    LUNG CANCER, 2008, 60 (02) : 200 - 207
  • [37] RESOURCE UTILIZATION BY HISTOLOGY FOR PEMETREXED AS MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL
    Zielinski, C.
    Feng, J.
    Gangadharan, V.
    Zhang, Y.
    Metzner, D.
    Hongming, P.
    Liepa, A. M.
    Peterson, P.
    Orlando, M.
    Oramas, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 97 - 98
  • [38] A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa
    Pirker, Robert
    Ramlau, Rodryg
    Schuette, Wolfgang
    Zatloukal, Petr
    Ferreira, Irene
    Lillie, Tom
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S433 - S434
  • [39] Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer
    Cheng, Ying
    Han, Liang
    Wu, Lin
    Chen, Jun
    Sun, Hongmei
    Wen, Guilan
    Ji, Yinghua
    Zimina, Anastasia
    Shi, Jianhua
    Pan, Zhijie
    Shi, Jinsheng
    Wang, Xicheng
    Yang, Fang
    Yang, Xinyi
    Chen, Mengkai
    Zhong, Shiqi
    Wang, Qingyu
    Li, Jing
    Cheng, Jiancheng
    Ling, Chen
    Shan, Yongqiang
    Zhu, Jun
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
    Cheng, Ying
    Chen, Jianhua
    Zhang, Wei
    Xie, Chao
    Hu, Qun
    Zhou, Ningning
    Huang, Chun
    Wei, Shihong
    Sun, Hong
    Li, Xingya
    Yu, Yan
    Lai, Jinhuo
    Yang, Huaping
    Fang, Haohui
    Chen, Hualin
    Zhang, Peng
    Gu, Kangsheng
    Wang, Qiming
    Shi, Jianhua
    Yi, Tienan
    Xu, Xingxiang
    Ye, Xianwei
    Wang, Daqing
    Xie, Conghua
    Liu, Chunling
    Zheng, Yulong
    Lin, Daren
    Zhuang, Wu
    Lu, Ping
    Yu, Guohua
    Li, Jinzhang
    Gu, Yuhai
    Li, Baolan
    Wu, Rong
    Jiang, Ou
    Wang, Zaiyi
    Wu, Guowu
    Lin, Haifeng
    Zhong, Diansheng
    Xu, Yanhua
    Shu, Yongqian
    Wu, Di
    Chen, Xingwu
    Wang, Jie
    Wang, Minghui
    Yang, Runxiang
    NATURE MEDICINE, 2024, 30 (10) : 1819 - 1822
12345